Renal transplantation Phase III results indicated that FTY720 in combination with cyclosporine provides no benefit over the current standard of care. Therefore, all clinical trials have been stopped. FTY720 is currently in Phase III trials to test is safety and efficacy in patients with relapsing-remitting multiple sclerosis.
Please let me know if you have any additional questions.
Julie Morrow, PhD
Global PR Manager, Neuroscience
Users browsing this forum: No registered users